Sarolaner

Sarolaner
Clinical data
Trade namesSimparica
Other namesPF-6450567
ATCvet code
Legal status
Legal status
Identifiers
  • 1-[6-[(5S)-5-(3,5-Dichloro-4-fluorophenyl)-5-(trifluoromethyl)-4H-1,2-oxazol-3-yl]spiro[1H-2-benzofuran-3,3'-azetidine]-1'-yl]-2-methylsulfonylethanone
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.234.000 Edit this at Wikidata
Chemical and physical data
FormulaC23H18Cl2F4N2O5S
Molar mass581.36 g·mol−1
3D model (JSmol)
  • CS(=O)(=O)CC(=O)N1CC2(C1)OCc1cc(C3=NO[C@@](c4cc(Cl)c(F)c(Cl)c4)(C(F)(F)F)C3)ccc12
  • InChI=1S/C23H18Cl2F4N2O5S/c1-37(33,34)9-19(32)31-10-21(11-31)15-3-2-12(4-13(15)8-35-21)18-7-22(36-30-18,23(27,28)29)14-5-16(24)20(26)17(25)6-14/h2-6H,7-11H2,1H3/t22-/m0/s1
  • Key:FLEFKKUZMDEUIP-QFIPXVFZSA-N

Sarolaner, sold under the brand name Simparica, is an ectoparasiticide veterinary medication for the treatment of flea and tick infestations in dogs.[7][8] It is also used off-label to control sarcoptic mange and demodectic mange.[8]

Sarolaner is also a component of the combination drug Simparica Trio, which contains sarolaner, moxidectin, and pyrantel.[9][10] It is used for prevention of heartworm disease caused by Dirofilaria immitis; treat and prevent flea infestations; treat and control tick infestations with the lone star tick, Gulf Coast tick, American dog tick, black-legged tick, and brown dog tick; and treat and control roundworm and adult hookworm infections.[11]

Sarolaner is also an ingredient in feline combination antiparasitic Revolution Plus (or Stronghold Plus[12]), which contains sarolaner and selamectin and is used for prevention of sarcoptic mange, feline hookworms, feline roundworms, ear mites, and heartworms, as well as treating and preventing fleas and ticks.[13]

References

[edit]
  1. ^ "Notice: Prescription Drug List (PDL): Multiple additions [2016-08-09]". Health Canada. 9 August 2016. Retrieved 10 July 2024.
  2. ^ "Drug and medical device highlights 2018: Helping you maintain and improve your health". Health Canada. 14 October 2020. Archived from the original on 17 April 2024. Retrieved 10 July 2024.
  3. ^ "Drug and medical device highlights 2019: Helping you maintain and improve your health". Health Canada. 18 November 2020. Retrieved 10 July 2024.
  4. ^ "Simparica". U.S. Food and Drug Administration (FDA). Archived from the original on 10 July 2024. Retrieved 12 December 2022.
  5. ^ "Simparica EPAR". European Medicines Agency. 18 December 2015. Archived from the original on 10 July 2024. Retrieved 13 June 2024.
  6. ^ "MiPet Easecto EPAR". European Medicines Agency. 23 February 2018. Archived from the original on 10 July 2024. Retrieved 13 June 2024.
  7. ^ McTier TL, Chubb N, Curtis MP, Hedges L, Inskeep GA, Knauer CS, et al. (May 2016). "Discovery of sarolaner: A novel, orally administered, broad-spectrum, isoxazoline ectoparasiticide for dogs" (PDF). Veterinary Parasitology. 222: 3–11. doi:10.1016/j.vetpar.2016.02.019. PMID 26961590. Archived (PDF) from the original on 4 November 2020. Retrieved 13 March 2022.
  8. ^ a b Gollakner R. "Sarolaner". vcahospitals.com. VCA Hospitals. Archived from the original on 27 June 2021. Retrieved 26 June 2021.
  9. ^ "Simparica Trio". U.S. Food and Drug Administration (FDA). Archived from the original on 9 December 2022. Retrieved 12 December 2022.
  10. ^ "Simparica Trio EPAR". European Medicines Agency. 14 October 2019. Archived from the original on 15 June 2024. Retrieved 15 June 2024.
  11. ^ "FDA Approves Simparica Trio, a Combination Drug for Heartworm and Other Parasites". U.S. Food and Drug Administration (FDA). 2 March 2020. Archived from the original on 24 September 2021. Retrieved 26 June 2021.
  12. ^ "Stronghold Plus". European Medicines Agency. 9 March 2017. Archived from the original on 10 July 2024. Retrieved 12 December 2022.
  13. ^ "Revolution Plus". U.S. Food and Drug Administration (FDA). Archived from the original on 10 July 2024. Retrieved 12 December 2022.